Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 999 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cream Clear all
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

NCT00540605
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 4 Interventional

An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis

NCT07725822
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Nail Psoriasis
Interventions
Roflumilast 0.3% topical cream
Drug
Lead sponsor
Modern Research Associates, PLLC
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessing the Effects of Tretinoin Cream on Human Skin With Optical Imaging Technologies

NCT02410980
View directory record Official record
Conditions
Collagen Fibril Alteration
Interventions
Tretinoin cream 0.1%
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
45 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 4 Interventional Results available

A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

NCT06336629
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% & Duac gel
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma

NCT01792505
View directory record Official record
Conditions
Malignant Glioma
Interventions
Dendritic Cell Vaccine in combination with Imiquimod cream
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 2 Interventional

IMX-150 Cream for Diabetic Neuropathy

NCT00641953
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
IMX-150, Placebo
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Brooksville, Florida • Jupiter, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

How do You Take Your Coffee Before Anesthesia

NCT04786691
View directory record Official record
Conditions
Anesthesia, Aspiration, Fasting
Interventions
Addition of half and half to coffee, Addition of non-dairy creamer to coffee, Black
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT06548360
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Acute Pain on Cognitive Performance in Young Adults

NCT05625776
View directory record Official record
Conditions
Pain, Acute, Cognition
Interventions
pain delivery with capsaicin and heat, distractor delivery with sensory TENS
Procedure
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 27, 2026, 8:13 AM EDT
Not listed Phase 1Phase 2 Interventional

Treatment of Chronic Migraine Headaches.

NCT03220113
View directory record Official record
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

Topical Anti-Androgens in Pilonidal Sinus Disease

NCT06286397
View directory record Official record
Conditions
Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
Interventions
1% Clascoterone, Vehicle Cream
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT02886715
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Tazorac®, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated Phase 2 Interventional Results available

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

NCT01692626
View directory record Official record
Conditions
Rash
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Early Phase 1 Interventional

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

NCT05838599
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Imiquimod, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 4 Interventional Results available

VANOS Cream and Skin Barrier Function

NCT00819507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated Early Phase 1 Interventional

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

NCT02197182
View directory record Official record
Conditions
Bacterial Vaginosis (BV)
Interventions
LUXSOL copper containing cream, Metronidazole gel
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CEE321
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

NCT04059523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, Retin-A® 0.1% Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated Not applicable Interventional Results available

Adjunctive Transcranial Direct Current Stimulation

NCT02665988
View directory record Official record
Conditions
Chronic Pain, Psychiatric Disorders
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 27, 2026, 8:13 AM EDT